Animab is founded on four patent families that cover technologies ensuring better performance, higher weight gain, better feed conversion and good physiological development with emphasis on livestock.
Oral antibodies that improve gut health
Fewer infections. Fewer antimicrobials. Better animal performance. Advances in biotechnology now make it possible. Through its antibody-based approach that targets intestinal pathogens, Animab helps protect piglets during their most fragile post-weaning stage.Discover our technology
The future belongs to the bold
Animab integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies and sustainability.Meet our team
Research with global impact
Animab is backed by a European investor syndicate with the ambition to bring this proven concept to the market as a commercial product.
From the production and purification of antibodies to its formulation and distribution, Animab's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed.
“Together with the labs of Profs. Ann Depicker (VIB-Ghent University) and Henri De Greve (VIB-VUB Center), our cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. While the antibody technology may have potential uses in various areas, Animab focuses on fighting pathogen infections in animal gastrointestinal tracts.”
VIB Ghent University Center for Medical Biotechnology
Yes, I want to know more about Animab